Self-Guided Digital Intervention for Depression in Adolescents: Feasibility and Preliminary Efficacy Study.
adolescents
behavioral activation
cognitive behavioral therapy
depression
digital health
mobile interventions
mobile phone
young adults
Journal
JMIR formative research
ISSN: 2561-326X
Titre abrégé: JMIR Form Res
Pays: Canada
ID NLM: 101726394
Informations de publication
Date de publication:
22 Nov 2023
22 Nov 2023
Historique:
received:
06
10
2022
accepted:
25
07
2023
revised:
21
06
2023
medline:
22
11
2023
pubmed:
22
11
2023
entrez:
22
11
2023
Statut:
epublish
Résumé
Depression in adolescents is a large and growing problem; however, access to effective mental health care continues to be a challenge. Digitally based interventions may serve to bridge this access gap for adolescents in need of care. Digital interventions that deliver components of cognitive behavioral therapy (CBT) have been shown to reduce symptoms of depression, and virtual reality (VR) may be a promising adjunctive component. However, research on these types of treatments in adolescents and young adults is limited. This study aims to evaluate the feasibility, acceptability, and preliminary efficacy of Spark (v1.0), a 5-week, self-guided, CBT-based digital program using a mobile app and VR experiences to target symptoms of depression in adolescents. A single-arm, open-label study of the Spark program was conducted with a community sample of 30 adolescents and young adults aged 12 to 21 years with self-reported moderate to severe depression symptoms. Participants completed a weekly depression assessment (Patient Health Questionnaire-8) in the app during the 5-week intervention period as well as web-based baseline, postintervention, and 1-month follow-up self-report assessments. The participants also completed a qualitative postintervention interview. For participants aged <18 years, caregivers completed assessments at baseline and postintervention time points. Feasibility outcomes included recruitment rate (the proportion of participants who enrolled in the study divided by the total number of participants screened for eligibility) and retention rate (the proportion of participants who completed postintervention assessments divided by the total number of participants who received the intervention). Acceptability outcomes included engagement with the program and quantitative and qualitative feedback about the program. Preliminary efficacy was evaluated based on the Patient Health Questionnaire-8. The study recruitment (31/66, 47%) and retention (29/30, 97%) rates were high. Participants provided higher ratings for the ease of use of the Spark program (8.76 out of 10) and their enjoyment of both the mobile app (7.00 out of 10) and VR components (7.48 out of 10) of the program, whereas they provided lower ratings for the program's ability to improve mood (4.38 out of 10) or fit into their daily routines (5.69 out of 10). We observed a clinically and statistically significant reduction in depression scores at postintervention (mean difference 5.36; P<.001) and 1-month follow-up (mean difference 6.44; P<.001) time points. The Spark program was found to be a feasible and acceptable way to deliver a self-guided CBT-focused intervention to adolescents and young adults with symptoms of depression. Preliminary data also indicated that the Spark program reduced the symptoms of depression in adolescents and young adults. Future studies should evaluate the efficacy of this intervention in an adequately powered randomized controlled trial. ClinicalTrials.gov NCT04165681; https://classic.clinicaltrials.gov/ct2/show/NCT04165681.
Sections du résumé
BACKGROUND
BACKGROUND
Depression in adolescents is a large and growing problem; however, access to effective mental health care continues to be a challenge. Digitally based interventions may serve to bridge this access gap for adolescents in need of care. Digital interventions that deliver components of cognitive behavioral therapy (CBT) have been shown to reduce symptoms of depression, and virtual reality (VR) may be a promising adjunctive component. However, research on these types of treatments in adolescents and young adults is limited.
OBJECTIVE
OBJECTIVE
This study aims to evaluate the feasibility, acceptability, and preliminary efficacy of Spark (v1.0), a 5-week, self-guided, CBT-based digital program using a mobile app and VR experiences to target symptoms of depression in adolescents.
METHODS
METHODS
A single-arm, open-label study of the Spark program was conducted with a community sample of 30 adolescents and young adults aged 12 to 21 years with self-reported moderate to severe depression symptoms. Participants completed a weekly depression assessment (Patient Health Questionnaire-8) in the app during the 5-week intervention period as well as web-based baseline, postintervention, and 1-month follow-up self-report assessments. The participants also completed a qualitative postintervention interview. For participants aged <18 years, caregivers completed assessments at baseline and postintervention time points. Feasibility outcomes included recruitment rate (the proportion of participants who enrolled in the study divided by the total number of participants screened for eligibility) and retention rate (the proportion of participants who completed postintervention assessments divided by the total number of participants who received the intervention). Acceptability outcomes included engagement with the program and quantitative and qualitative feedback about the program. Preliminary efficacy was evaluated based on the Patient Health Questionnaire-8.
RESULTS
RESULTS
The study recruitment (31/66, 47%) and retention (29/30, 97%) rates were high. Participants provided higher ratings for the ease of use of the Spark program (8.76 out of 10) and their enjoyment of both the mobile app (7.00 out of 10) and VR components (7.48 out of 10) of the program, whereas they provided lower ratings for the program's ability to improve mood (4.38 out of 10) or fit into their daily routines (5.69 out of 10). We observed a clinically and statistically significant reduction in depression scores at postintervention (mean difference 5.36; P<.001) and 1-month follow-up (mean difference 6.44; P<.001) time points.
CONCLUSIONS
CONCLUSIONS
The Spark program was found to be a feasible and acceptable way to deliver a self-guided CBT-focused intervention to adolescents and young adults with symptoms of depression. Preliminary data also indicated that the Spark program reduced the symptoms of depression in adolescents and young adults. Future studies should evaluate the efficacy of this intervention in an adequately powered randomized controlled trial.
TRIAL REGISTRATION
BACKGROUND
ClinicalTrials.gov NCT04165681; https://classic.clinicaltrials.gov/ct2/show/NCT04165681.
Identifiants
pubmed: 37991839
pii: v7i1e43260
doi: 10.2196/43260
pmc: PMC10701656
doi:
Banques de données
ClinicalTrials.gov
['NCT04165681']
Types de publication
Journal Article
Langues
eng
Pagination
e43260Informations de copyright
©Ian Miller, Emily Peake, Gabriel Strauss, Elise Vierra, Xin Koepsell, Brandon Shalchi, Aarthi Padmanabhan, Jessica Lake. Originally published in JMIR Formative Research (https://formative.jmir.org), 22.11.2023.
Références
JMIR Ment Health. 2020 Aug 7;7(8):e17204
pubmed: 32763881
J Anxiety Disord. 2019 Jan;61:27-36
pubmed: 30287083
Psychiatr Serv. 2020 Apr 1;71(4):312-318
pubmed: 31847739
BMC Psychiatry. 2010 Dec 30;10:113
pubmed: 21192795
Neurosci Biobehav Rev. 2008;32(1):1-19
pubmed: 17570526
Internet Interv. 2021 Oct 09;26:100468
pubmed: 34703772
J Gen Intern Med. 2001 Sep;16(9):606-13
pubmed: 11556941
J Am Acad Child Adolesc Psychiatry. 2002 Apr;41(4):367-76; discussion 376-7
pubmed: 11931592
J Anxiety Disord. 2015 Jan;29:83-92
pubmed: 25527900
BMC Psychol. 2021 Oct 7;9(1):150
pubmed: 34615559
Arch Intern Med. 2006 May 22;166(10):1092-7
pubmed: 16717171
Behav Modif. 2011 Mar;35(2):111-61
pubmed: 21324944
Conscious Cogn. 2013 Sep;22(3):779-87
pubmed: 23727712
Behav Modif. 2013 Jul;37(4):568-90
pubmed: 23585557
Eur Psychiatry. 2019 Apr;57:33-45
pubmed: 30658278
Front Psychol. 2018 Nov 30;9:2364
pubmed: 30555387
J Youth Adolesc. 2015 Jan;44(1):90-113
pubmed: 25115460
J Child Psychol Psychiatry. 2017 Apr;58(4):474-503
pubmed: 27943285
J Med Internet Res. 2009 Apr 24;11(2):e13
pubmed: 19403466
Eur Child Adolesc Psychiatry. 2017 Jun;26(6):623-647
pubmed: 28054223
Clin Child Fam Psychol Rev. 2019 Jun;22(2):147-171
pubmed: 30229343
Soc Psychiatry Psychiatr Epidemiol. 2019 Aug;54(8):987-996
pubmed: 30929042
Internet Interv. 2021 Jun 17;25:100408
pubmed: 34401367
Arch Pediatr Adolesc Med. 2010 Dec;164(12):1112-7
pubmed: 21135339
J Anxiety Disord. 2019 Jan;61:45-54
pubmed: 30054173
Psychol Aging. 1997 Jun;12(2):277-87
pubmed: 9189988
Front Psychiatry. 2019 Nov 13;10:759
pubmed: 31798468
Clin Psychol Rev. 2010 Aug;30(6):608-20
pubmed: 20677369
J Affect Disord. 2020 Feb 15;263:413-419
pubmed: 31969272
BMC Psychiatry. 2019 Jan 21;19(1):35
pubmed: 30665384
J Behav Health Serv Res. 2008 Jan;35(1):107-14
pubmed: 17975730
Lancet. 2016 Jun 11;387(10036):2423-78
pubmed: 27174304
Behav Cogn Psychother. 2018 Mar;46(2):182-194
pubmed: 28756787
J Ment Health Policy Econ. 2004 Sep;7(3):133-45
pubmed: 15478992
BJPsych Open. 2019 Jan;5(1):e15
pubmed: 30762511
Psychiatry Res. 2016 Sep 30;243:469-94
pubmed: 27517643
Internet Interv. 2022 Jan 17;27:100496
pubmed: 35257001
Psychiatr Clin North Am. 2022 Mar;45(1):179-189
pubmed: 35219437
J Affect Disord. 2004 Jul;81(1):61-6
pubmed: 15183601
J Can Acad Child Adolesc Psychiatry. 2011 May;20(2):112-9
pubmed: 21541100
Lancet Psychiatry. 2018 Aug;5(8):625-632
pubmed: 30007519
Lancet. 2019 Jun 15;393(10189):e42-e43
pubmed: 30482607
PLoS One. 2013;8(1):e55003
pubmed: 23383029
BMC Psychiatry. 2015 Dec 01;15:305
pubmed: 26627041
J Ment Health. 2015;24(5):321-32
pubmed: 26017625
J Affect Disord. 2010 Dec;127(1-3):185-90
pubmed: 20573404
Depress Anxiety. 2012 Feb;29(2):85-93
pubmed: 22065564
Psychol Med. 2017 Oct;47(14):2393-2400
pubmed: 28325167
Soc Sci Med. 2010 Apr;70(7):985-93
pubmed: 20122768
Behav Res Ther. 2015 Apr;67:1-18
pubmed: 25727678
Eur Neuropsychopharmacol. 2012 Nov;22(11):787-99
pubmed: 22030230
J Med Internet Res. 2013 Oct 17;15(10):e231
pubmed: 24135213
J Adolesc Health. 2016 Oct;59(4):401-10
pubmed: 27267141
J Consult Clin Psychol. 2009 Dec;77(6):1021-32
pubmed: 19968379
Br J Clin Psychol. 2022 Jun;61(2):287-305
pubmed: 34569066
PLoS One. 2012;7(12):e48469
pubmed: 23300515
J Med Internet Res. 2020 Mar 18;22(3):e16106
pubmed: 32186519
BMJ Open. 2017 Jan 27;7(1):e012834
pubmed: 28132000
Med Care. 1988 Jul;26(7):724-35
pubmed: 3393032
PLoS One. 2016 May 02;11(5):e0154248
pubmed: 27135410
NPJ Digit Med. 2020 Jun 15;3:85
pubmed: 32566763
Digit Health. 2022 Jul 3;8:20552076221104672
pubmed: 35811758
Am J Psychiatry. 2009 Jan;166(1):64-73
pubmed: 19047324
J Clin Child Adolesc Psychol. 2016;45(3):291-304
pubmed: 25602170
J Affect Disord. 2009 Apr;114(1-3):163-73
pubmed: 18752852
Community Ment Health J. 2014 Feb;50(2):221-8
pubmed: 23283487
Explore (NY). 2023 May-Jun;19(3):310-318
pubmed: 36002363
PLoS One. 2018 Oct 17;13(10):e0204494
pubmed: 30332407
Cureus. 2020 May 21;12(5):e8224
pubmed: 32582485
Aust N Z J Psychiatry. 2018 Jan;52(1):59-67
pubmed: 28486819
Curr Psychiatry Rep. 2009 Dec;11(6):453-8
pubmed: 19909667
Biopsychosoc Med. 2021 Oct 3;15(1):16
pubmed: 34602086
Child Adolesc Psychiatr Clin N Am. 2017 Jan;26(1):125-133
pubmed: 27837938